So-called “common mutations”, including del19 and L858R in exon 21, representing about 90% of all EGFR mutations, have shown a marked sensitivity to tyrosine kinase inhibitors (TKIs), whose introduction into the medical armory has significantly changed the prognosis of these patients and the therapeutic approach to lung cancer [4]. This evidence concerns the gene EGFR and lung cancer.